We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

46 hedge funds and large institutions have $73.3M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

10% more capital invested

Capital invested by funds: $66.8M → $73.3M (+$6.51M)

0% more funds holding

Funds holding: 46 → 46 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

Holders
46
Holders Change
–
Holders Change %
0%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$5.12M
2
AA
AQR Arbitrage
Connecticut
+$979K
3
CCM
CAAS Capital Management
New York
+$947K
4
MF
Magnetar Financial
Illinois
+$867K
5
PAMP
Polar Asset Management Partners
Ontario, Canada
+$455K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$6.1M
2
ACA
Arena Capital Advisors
California
-$959K
3
AMH
Apollo Management Holdings
New York
-$909K
4
FTCM
Fir Tree Capital Management
New York
-$428K
5
EAM
Exos Asset Management
New York
-$103K
Name Holding Trade Value Shares
Change 		Change in
Stake
GF
26
Gabelli Funds
New York
$718K – – –
GCIA
27
Gabelli & Co Investment Advisers
New York
$643K – – –
CSS
28
Cubist Systematic Strategies
Connecticut
$593K +$342K +34,896 +136%
WA
29
Whitebox Advisors
Minnesota
$494K – – –
PAMP
30
Polar Asset Management Partners
Ontario, Canada
$455K +$455K +46,500 New
TCA
31
Taconic Capital Advisors
New York
$455K +$455K +46,500 New
AGC
32
Angelo Gordon & Co
New York
$392K +$392K +40,000 New
ACM
33
Atalaya Capital Management
New York
$391K – – –
EAM
34
Exos Asset Management
New York
$356K -$103K -10,544 -23%
OAC
35
OMERS Administration Corp
Ontario, Canada
$342K – – –
VI
36
Vestcor Inc
New Brunswick, Canada
$342K – – –
KCM
37
Kawa Capital Management
Florida
$264K – – –
WRBC
38
W.R. Berkley Corp
Connecticut
$192K – – –
DIG
39
DeepCurrents Investment Group
New York
$174K – – –
SCM
40
Saba Capital Management
New York
$169K +$5.87K +600 +4%
SSA
41
Schonfeld Strategic Advisors
New York
$139K +$3.38K +345 +2%
LCM
42
Landscape Capital Management
New Jersey
$108K – – –
AA
43
Ancora Advisors
Ohio
$68K – – –
ACA
44
Arena Capital Advisors
California
$56K -$959K -98,025 -94%
UBS Group
45
UBS Group
Switzerland
$15K – – –
MF
46
Magnetar Financial
Illinois
$968 +$867K +88,596 +857%
Citadel Advisors
47
Citadel Advisors
Florida
– -$6.1M -625,916 Closed
AMH
48
Apollo Management Holdings
New York
– -$909K -93,288 Closed
SCC
49
Spring Creek Capital
Kansas
– -$488K -50,000 Closed
PCM
50
Prelude Capital Management
New York
– -$97K -10,000 Closed
1
2

EBAC Hedge Fund Activity: Q2 2022 in Review

46 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q2 2022, worth a combined $73.3M — up 9.8% from $66.8M a quarter earlier.

Fund positioning in EBAC was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 5 trimmed.

The largest buyer was Glazer Capital LLC, adding an estimated $5.12M. The largest seller was Citadel Advisors, exiting entirely with an estimated $6.1M sold.

  • 46 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $73.3M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q2 2022, up 9.8% quarter-over-quarter.
  • 5 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q2 2022 and 5 closed out, a net change of 0 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q2 2022 was Glazer Capital LLC, an estimated $5.12M added.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q2 2022 was Citadel Advisors, an estimated $6.1M sold.

Based on aggregated 13F filings for Q2 2022.